Date: 2014-10-15
Type of information: IPO
Company: Atara Biotherapeutics (USA - CA)
Investors:
Amount: $ 55 millio
Funding type: IPO
Planned used:
Others: * On October 15, 2014, Atara Biotherapeutics, a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $11.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol \"ATRA\" on October 16, 2014. In addition, Atara has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Atara at the initial public offering price to cover over-allotments, if any. The offering is expected to close on October 21, 2014, subject to customary closing conditions. Goldman, Sachs & Co. and Citigroup Global Markets Inc. are acting as joint book-running managers for the proposed offering. Jefferies LLC is acting as co-manager. A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on October 15, 2014.
Therapeutic area: Cancer - Oncology - Kidney diseases - Renal diseases
